Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality-of-Life Instruments 1985–2010 by Rehal, Balvinder & Armstrong, April
Health Outcome Measures in Atopic Dermatitis: A
Systematic Review of Trends in Disease Severity and
Quality-of-Life Instruments 1985–2010
Balvinder Rehal, April Armstrong*
Department of Dermatology, University of California Davis, Davis, California, United States of America
Abstract
Background: A number of disease-severity and quality-of-life (QoL) instruments have emerged in atopic dermatitis (AD) in
the last decade.
Objectives: To identify trends in outcomes instruments used in AD clinical trials and to provide a useful summary of the
dimensions and validation studies for the most commonly used measures.
Method: All randomized control trials (RCTs) from 1985 to 2010 in the treatment of AD were examined.
Results: Among the 791 RCTs reviewed, we identified 20 disease-severity and 14 QoL instruments. Of these outcomes
instruments, few have been validated. SCORAD, EASI, IGA and SASSAD were the most commonly used disease-severity
instruments and CDLQI, DFI, DLQI and IDQOL were the most frequently used QoL measures.
Limitations: The small number of RCTs using QoL scales makes identifying trends for QoL instruments difficult.
Conclusion: Overall, there is an increase in the use of disease-severity and QoL instruments in AD clinical trials.
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Introduction
Atopic dermatitis is a chronic, inflammatory skin disease that
affects patients’ physical and psychosocial wellbeing. The burden
of atopic dermatitis has been documented in the medical literature
[1,2]. Patients suffering from atopic dermatitis often experience
embarrassment from the skin lesions, and severe disease can
adversely affect social interactions and personal relationships. The
symptoms of atopic dermatitis, notably pruritus, can be intractable
and lead to significant emotional distress and sleep loss [3].
Despite continuing efforts in developing new treatments for atopic
dermatitis, scarce literature exists that evaluates disease-severity and
quality-of-life (QoL) outcome measures in AD [4,5,6,7]. This
systematic review examines the trends in outcomes instruments,
specifically disease-severity and QoL instruments, in randomized
controlled trials (RCT) in the treatment of AD published between
1985 to 2010. We discuss the most frequently used disease-severity
and QoL measures in terms of their dimensions (aspects of AD that
the instrument measures) and validation studies that have supported
their increased use in clinical trials.
Methods
To examine the disease and QoL outcome measures used in
atopic dermatitis trials, we conducted a systematic review of RCTs
for AD from 1985 to 2010 in the U.S. National Library of
Medicine using the Medline search engine and in the electronic
database, Scopus, which includes the EMBASE database. In
Medline we applied the Medical Subject Headings search terms
‘‘atopic dermatitis’’ and ‘‘treatment’’ and limited the search to
human RCTs published in the English language from January 1,
1985 to July 14, 2010. In Scopus, we searched for RCTs in atopic
dermatitis using the search ‘‘TITLE-ABS-KEY(atopic dermatitis)
AND (TITLE-ABS-KEY(randomized control trial*) OR TITLE-
ABS-KEY(RCT)).’’
Results
In Medline, our search identified an initial group of 552 studies
published between 1985 and 20010 in AD. Of these 552 studies,
195 were excluded either because they were not RCTs, not
pertaining to atopic dermatitis studies, not in English, or no
outcome measures were used (Figure 1). In Scopus our search
generated 239 studies from 1985–2010. After cross-referencing the
list of studies with our Medline search, we were left with 141
articles. Of these, 116 were excluded for the reasons listed above.
After exclusion, 382 studies were reviewed from both Medline and
Scopus.
A total of 20 disease-severity scales and 14 QoL scales were used
in the RCTs for the treatment of atopic dermatitis. We list the
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respectively.
The most frequently used disease-severity instruments from
1985 to 2010 were the Severity scoring of atopic dermatitis
(SCORAD), Eczema Area and Severity Index (EASI), Investiga-
tors’ Global Assessment (IGA) and Six Area, Six Sign Atopic
Dermatitis (SASSAD) (Table 1). SCORAD was the most
frequently used scale; it was used in 113 out of 382 RCTs
(30%). The next most frequently used scale was the EASI, which
was used in 63 out of 382 RCTs (16%), followed by the IGA that
Figure 1. Excluded studies.
doi:10.1371/journal.pone.0017520.g001
Table 1. Severity of disease scales.
Scale Clinical signs
Disease
extent
Subjective
Sx
# of
studies
used in
Erythema
Edema/
papulation
oozing/
crusts excoriation lichenification
dryness/
scaling
Severity scoring of atopic dermatitis (SCORAD) * * * * * * * 76
Eczema Area and Severity Index (EASI) * * * * * 51
Investigators’ Global Assessment (IGA) * * * 41
Six Area, Six Sign Atopic Dermatitis (SASSAD) * * * * * * * 14
Investigators’ Global Atopic Dermatitis
Assessment (IGADA)
** * * * * * 4
Costa et al * * * * * * * * 3
Leiciester Sign Score (LSS) * * * * * * 2
Visual Analogue Scale (VAS) pruritus *2
Total Severity Score (TSS) * * * * * * 2
Physicians Global Assessment (PGA) * * * 2
Intensity Item Score Aggregate (IISA) * * * * * * * * 1
Atopic Dermatitis Severity Index (ADSI) * * * * * * 1
Investigators’ Static Global Assessment (ISGA) * * * * * * 1
Nottingham Eczema Severity Score (NESS) ** 1
Investigators’ Global Assessment Score (IGAS) * * *1
Dry skin are and severity index (DASI) * * * * 1
Atopic Dermatitis Area and Severity
Index (ADASI)
** * * * * * 1
Total body severity assessment (TBSA) * * * * * * 1
doi:10.1371/journal.pone.0017520.t001
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out of 382 RCTs (5%). The four most commonly used scales,
SCORAD, EASI, IGA and SASSAD, were used in the majority of
RCTs: 242 out of 382 (63%). The remaining 14 scales were used
in 57 out of 382 RCTs (15%).
The trend for disease-severity scales showed that the number of
disease-severity instruments used in clinical trials increased
dramatically from 1985 to 2010 (Figure 2). Specifically, SCORAD
was used in 4% of RCTs from 1985–1997 and 40% RCTs from
1998–2010. SCORAD had its peak usage from 2005 to 2010.
EASI, IGA and SASSAD were also used more commonly from
1985–2010 (Figure 2). From 1985–1997, no RCTs used EASI,
IGA or SASSAD. EASI also had its peak usage from 2005 to
2010. To our knowledge, IGA has not been validated to date, but
its usage has been nearly identical to that of EASI (Figure 2). Out
of the 48 RCTs that used IGA, 32 trials used IGA in conjunction
with EASI (67%).
Among the 382 RCTs, 67 studies employed QoL instruments.
Of the studies that used QoL outcomes measures, the Children’s
Dermatology Life Quality Index (CDLQI) was the most frequently
used (33%), followed by the Dermatitis Family Impact (DFI)
(15%), the Dermatology Life Quality Index (DLQI) (13%) and the
Infant’s Dermatology Life Quality Index.
(IDQOL) (12%) (Table 2). Overall, the use of QoL scales in
RCTs has increased from 1985 to 2010 (Figure 3). None of the
four most commonly used QoL instruments, CDLQI, DFI, DLQI
or IDQOL were used between 1985–1997.
Common Disease-Severity Scales in Atopic Dermatitis:
Dimensions and Evidence for Validation
Severity Scoring of Atopic Dermatitis (SCORAD). From
1985 to 2010, SCORAD was the most widely used disease-severity
scale in atopic dermatitis. SCORAD was used in 113 out of the
382 studies that met our search criteria (30%). It was developed in
Table 2. Quality of life scales.
Scale Questions
# Studies
used in
Severity itching mood sleep
dressing/
clothes
leisure
activities treatment
Parent
mood
Parent
sleep
family
disruption/
tension
Children’s Dermatology
Life Quality Index (CDLQI)
* * * *** 1 3
Dermatology Life Quality
Index (DLQI)
* * *** 8
Infant’s Dermatology
Quality of Life (IDQOL)
* * * * *** 7
Dermatitis Family Impact (DFI) * * * * * 6
Parent’s Index of Quality of Life
in Atopic Dermatitis (PIQoL-AD)
** * * * 2
Quality of Life Index for Atopic
Dermatitis (QoLIAD)
** * 2
Short Form Health Survey (SF-36) * * * 2
Parents of Children with Atopic
Dermatitis (PQoL–AD)
** 1
German Instrument for the
assessment of Quality of Life
in Skin Diseases (DIELH)
** * * 1
Eczema Disability Index (EDI) * * 1
Skindex-29 * * * * 1
doi:10.1371/journal.pone.0017520.t002
Figure 2. Trends in Disease Severity Instruments 1985–2010.
doi:10.1371/journal.pone.0017520.g002
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SCORAD index uses the rule of nines to assess disease extent and
evaluates five clinical characteristics to determine disease severity:
(1) erythema, (2) edema/papulation, (3) oozing/crusts, (4)
excoriation and (5) lichenification. SCORAD also assesses
subjective symptoms of pruritus and sleep loss with Visual
Analogue Scales (VAS) [8]. These three aspects: extent of
disease, disease severity and subjective symptoms combine to
give a maximum possible score of 103. Although it is a combined
score, the three aspects can be separated and used individually if
necessary. Of all the severity scales used in atopic dermatitis, it is
the most widely validated disease-severity instrument [9].
SCORAD has been found to be valid and reliable, and it has
shown excellent agreement with global assessments of disease
severity [8,9,10,11,12,13,14,15,16,17,18,19,20,21,22]. However,
some studies have shown interobserver variation in scoring
lichenification and extent of disease [8,9,10,18,20,23].
Eczema Area and Severity Index (EASI). EASI was the
second most commonly used scale in our review of the literature. It
was used in 63 out of 382 RCTs (16%). EASI was developed by
modifying the PASI (Psoriasis Area and Severity Index), a widely
accepted and standardized scoring system for psoriasis [24]. EASI
assesses extent of disease at four body sites and measures four
clinical signs: (1) erythema, (2) induration/papulation, (3)
excoriation, and (4) lichenification each on a scale of 0 to 3.
EASI confers a max score of 72 [25]. EASI evaluates two
dimensions of atopic dermatitis: disease extent and clinical signs.
Unlike the SCORAD, it does not assess symptoms like pruritus
and sleep loss. Some investigators express that subjective
symptoms may be the most important marker for assessing
patient morbidity and they may also be a good indicator for
disease severity. In a large validation study with a cohort of 1550
pediatric patients, EASI was found to have excellent validity,
internal consistency and sensitivity to change [26]. While EASI is a
valid and reliable instrument, most interobserver variability lies in
the dimension of induration/papulation [13,21,25,26,27].
Investigators’ Global Assessment (IGA). IGA was the
third most common scale, used in 48 out of 382 RCTs (13%). IGA
allows investigators to assess overall disease severity at one given
time point, and it consists of a 6-point severity scale from clear to
very severe disease (0=clear, 1=almost clear, 2=mild disease,
3=moderate disease, 4=severe disease and 5=very severe
disease) [28]. IGA uses clinical characteristics of erythema,
infiltration, papulation, oozing and crusting as guidelines for the
overall severity assessment [28]. To our knowledge, IGA has not
been validated as an outcome measure [7]. However, IGA has
been used to validate other outcome scales as one ‘‘gold standard.’’
[9,26] While the combined use of IGA with another validated
scale does not make IGA itself a stand-alone, validated instrument,
IGA appears to correlate well with the EASI and is considered an
instrument with reasonable face validity. Potential weaknesses of
IGA include lack of responsiveness and discrimination for disease
severity and lack of subjective symptoms.
Six-Area, Six-Sign Atopic Dermatitis (SASSAD). SASSAD
was used in 18 out of 382 RCTs (5%), which ranks SASSAD as the
fourth most commonly used scale. SASSAD assesses six clinical
signs of disease severity (erythema, exudation, dryness, cracking,
excoriation, and lichenification) at six body sites (head/neck,
trunk, arms, hands, legs and feet). Each clinical sign on a given
body site is graded on a scale of 0–3, and the scale confers a
maximum score of 108 [29]. SASSAD does not assess subjective
symptoms. The SASSAD is sensitive to changes in topical steroid
requirements, pruritus, and sleep loss [30,31,32,33,34]. In a small
reliability study involving 6 patients, there was interobserver
variation for dryness and lichenification [35].
Quality-of-Life Instruments in Atopic Dermatitis:
Dimensions and Evidence for Validation
Children’s Dermatology Life Quality Index (CDLQI).
CDLQI was the most common QoL instrument from our
search, used in 22 out of 382 RCTs (6%). Drs. Lewis-Jones and
Finlay developed and validated CDLQI in 1995, with the purpose
of measuring the QoL in children with skin disease [36]. The
questionnaire was designed for children ages 4 through 16.
CDLQI is completed by the child with the help of an adult if
necessary, preferably a parent. The questionnaire consists of 10
questions that encompass different aspects of a child’s life that
could be affected by their skin disease. The instrument includes
physical symptoms, such as itching and sleep loss, as well as
psychosocial questions regarding friendships, bullying, school
performance, sports participation, and enjoyment of vacation.
The questions are graded from 0–3, with a possible maximum
score of 30 with higher scores representing worse QoL. [36]. In the
initial validation study, children with atopic eczema accounted for
20% of all patients [36]. To determine test-retest repeatability,
CDLQI was used in a population of children without skin disease
[36].
Since its validation, CDLQI has been used in numerous studies
to determine the effectiveness of interventions in children with AD
[37,38]. CDLQI has been translated and validated in Cantonese
[39,40,41]. A cartoon version of CDLQI was validated in 2003,
which appears to be quicker and preferred by children [42].
Dermatitis Family Impact (DFI). The DFI questionnaire
was used in 10 out of 382 RCTs (2.6%), making it the second most
common quality of life scale used in our review. It was developed
in 1998 by Drs. Lawson, Lewis-Jones, Finlay, Reid and Owens to
Figure 3. Trends in Quality of Life Instruments 1985–2010.
doi:10.1371/journal.pone.0017520.g003
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atopic dermatitis [43]. It is designed to be completed by a
caretaker of the child, usually a parent, and consists of 10 questions
related to housework, food preparation and feeding, sleep, family
leisure activity, shopping, expenditure, fatigue, emotional distress
and relationships [43]. Each question is graded from 0–3 with
a maximum possible score of 30. DFI has been found to be
valid, reliable, and sensitive to change in multiple studies
[6,39,43,44,45,46,47,48]. Two studies that assessed validity of
the instrument were based on using separate components of the
DFI, as opposed to using the total score as was originally intended
by creators of the scale [43,46]. DFI has also been validated in
Malay and Portuguese [39,44,45,48].
Dermatology Life Quality Index (DLQI). DLQI was the
third most common QoL scale that was used in 9 out of 382 RCTs
(2.4%) in our review. DLQI was developed in 1994 by Drs. Finlay
and Khan to measure quality of life in routine clinical practice in
adults over age of 18 [49]. DLQI is a 10-item questionnaire that
inquires about skin symptoms, feelings of embarrassment, and how
skin disease has affected day-to-day activities, working and social
life. Similar to CDLQI, each question on DLQI is scored from 0
to 3 with a maximum score of 30 and high scores representing
worse QoL.
Both DLQI and CDLQI are specialty-specific but not disease-
specific QoL instruments. In the original article by Finlay and
Khan, patients with atopic dermatitis had the worst QoL as
measured by DLQI compared to the other skin diseases assessed in
the study [49]. DLQI has been extensively validated in multiple
studies [49,50,51]. A 10-year review of the literature found that
DLQI is highly specific for assessing decrements in QoL in
patients with atopic dermatitis compared with the general
population [51]. Specifically, patients with atopic eczema had a
mean score of 4.2 compared to 0.3 in a normal population [50,51].
DLQI has high repeatability, internal consistency, and sensitivity
to change [51].
Infants’ Dermatitis Quality of Life Index (IDQOL).
IDQOL was the fourth most common scale found in our
review, used in 8 out of 382 RCTs (2.1%) examined. It was
developed in 2001 by Drs. Lewis-Jones, Finlay, and Dykes to assess
QoL in infants with AD [52]. IDQOL is completed by the parents
of infants from birth to 4 years. The instrument consists of 10
questions regarding an infant or young child’s difficulties with
mood, sleep, bathing, dressing, play, mealtimes, other family
activities, and treatment [52]. Each question is graded from 0–3
with a maximum total score of 30. A higher number correlates
with a greater impairment of quality of life. An additional question
exists that is scored separately on a scale of 0–4 that asks for the
parents’ overall assessment of eczema severity. In the original
article the scale was validated with repeatability and sensitivity to
change confirmed [52]. The scale was further validated with
sensitivity to change confirmed and has been used in over 15
studies [43,53].
Discussion
Effective management of skin diseases begins with evaluation of
both clinical disease severity and health-related QoL. In
dermatology, the assessment of disease severity is frequently
condition-specific and uses defined, observable parameters
[54,55,56,57]. QoL refers to the impact of a disease on a patient’s
overall function and wellbeing [58]. While disease severity is
central for clinical evaluation and monitoring treatment response,
QoL measures are as important for determining the effect of a
disease or intervention on a patient’s general welfare.
In the last 25 years, 20 disease-severity scales and 14 QoL
instruments have been used in clinical trials involving patients with
atopic dermatitis. Despite the emergence of multiple disease-
severity and QoL instruments, few instruments have been
validated. The four most commonly used disease-severity scales
SCORAD, EASI, IGA, and SASSAD were used in 242 out of the
382 RCTs reviewed (63%). SCORAD, EASI, and SASSAD have
been extensively validated [7]. The four most commonly used
QoL instruments were DLQI, CDLQI, IDQOL, and DFI. All
four scales have demonstrated validity, reliability, and sensitivity to
change [36,47,51,52].
The use of four top disease-severity instruments in AD has
increased from 1985 to 2010 (Figure 2). For example, when we
compared instrument usage patterns between the period from
2000–2004 with that from 2005–2010, we found that SCORAD
usage increased by 106%; EASI usage increased by 165%; IGA
usage increased by 169%, and SASSAD usage decreased by 20%.
Over this ten-year period, IGA had the greatest rate of increase.
The greater increased rate of IGA usage may be attributed to its
ease of administration. Compared to IGA, EASI also experienced
a higher rate of adoption in clinical trials since 1985. The usage
patterns of EASI and IGA appear to parallel with each other,
which suggests researchers’ preference for both scales as objective
measures of AD.
The increased usage of disease severity scales appeared to
coincide with the publication of validation studies. SCORAD had
its peak usage from 2005 to 2010, which corresponded closely to
the publication of its validation studies from 2004 to 2006. EASI
also had its peak usage from 2005 to 2010, which coincided with
the publication of its validation studies in 2004 and 2005.
Among the four most commonly used QoL instruments, all
were used more commonly as the years progressed. One possible
explanation for this trend is that QoL measures have become as
important as disease-severity instruments for patient evaluation
and management. Of note, the four most common quality of life
scales were developed by the same group of physicians and are
similar in format and design. This may limit the diversity of the
scale and the variety of characteristics that are used when assessing
QoL in patients with atopic dermatitis. Additionally, our search of
the literature was limited to randomized controlled trials. Other
disease-specific quality of life instruments may exist that have not
been used in randomized control trials.
Another limitation of our review is that, out of 382 RCTs
examined, we identified 67 RCTs that used QoL measurements
(18%), which makes identifying trends for individual QoL
instruments difficult.
In this review, we identified trends for disease-severity and QoL
outcomes measurements in atopic dermatitis from 1985–2010. We
also summarized dimensions of the most commonly used scales
and cited evidence for their validation. Although the consistent use
of validated measures assessing disease severity and QoL in AD
was not observed 20 years ago, this study found a promising trend
of increased usage of validated instruments in clinical trials that
measure AD disease severity and QoL in the past decade.
Outcomes researchers in dermatology are encouraged to select
validated outcomes measures that provide accurate measurement
of disease dimensions and allow for comparison among studies.
This is the first systematic analysis of trends in the usage of
outcomes measures in dermatological research. We anticipate that
similar studies will be forthcoming in other disease areas within
dermatology that assess the use of outcomes instruments. This type
of study depicts the progression of a field’s research quality and
validity, and it encourages future outcomes researchers to devise
instruments that will be streamlined, valid, and reliable.
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